Sustainability
Essential Concepts
We at CMIC see our socially beneficial enterprises, such as in the pharmaceutical manufacturing industry/ medical center support and orphan drug supply as contributions to the improvement of our sustainability (an ability to carry on) in and of themselves. Additionally, we engage in activities for our various stake-holders, as we are aware that any activity based on CMIC’s Creed increases our sustainability all the more.
Each and every employee with noble intent and high ethics, taking positive steps forward in activities that contribute to society, so that we may fulfill our responsibilities as a good corporate citizen, and be a company entrusted by society.
Support for travel clinic service (medical examination and treatment) in Brazil
CMIC supports annual travel clinic service for Japanese immigrants in Brazil, which has been provided for over three generations by Dr. Emilio Moriguchi (CMIC’s consultant in Brazil).
Why travel clinic service?
Japanese immigrants arrived in the south of Brazil immediately after the end of the war cannot speak Portuguese and therefore are not able to visit local hospitals for examination or consultation.
Dr. Emilio Hideyuki Moriguchi, Japanese Brazilian doctor, has provided travel clinic service for such Japanese immigrants living in the south of Brazil for over three generations. There are many Japanese immigrants who look forward to the annual travel clinic. Dr. Emilio Moriguchi travels in a mobile medical van for over 3,000 km every year to reach out to them and provide medical care in Japanese.
CMIC Group’s Involvement
Following the economic growth in Brazil, the amount of public subsidy for the travel clinic service went down and Dr. Moriguchi’s out-of-pocket expenses have increased as a result. Under such circumstances, CMIC Group has started employee donations in 2014 in addition to corporate donations. CMIC Group will continue supporting Dr. Moriguchi in his wish to “continue travel clinic service for Japanese immigrants in the south of Brazil”.
CMIC Award for AIDS Researcher
CMIC Award is presented each year by The Japanese Society for AIDS Research (membership: approximately 2,000 persons) to one person whose innovative and superior achievements have contributed to the development of the Society, through activities in relation to the spread of HIV disease.
Taking Part in Rare Disease Day (RDD)
*The aim of Rare Disease Day (RDD) is to improve quality of life (QOL) for patients with rare/ intractable diseases through better diagnoses and treatments, with February 28th (February 29th in leap years) being so named, and RDD has now been held in approximately 100 countries around the world, since its inception in 2008 in Sweden.
Although rare diseases can affect over 7,000 people, diagnoses can often take time because of poor awareness, and it has been reported that there is an average 5 year wait before a diagnosis is reached, with patients changing hospital 7 times or more during that time.
We take part in RDD in Japan so that more people, through RDD activities, will have a deeper understanding of rare/ intractable diseases, and to make possible a society where patients suffering from refractory conditions and those who care for them may live life more at ease.
The CMIC group is involved in clinical trials for numerous orphan drugs (for rare diseases).
We wore badges and promoted consciousness-raising activities for a 1-month period in February, to increase community awareness of these patients on the part of healthcare practitioners and others, and, to help serve as a bridge between patients and their communities.
The CMIC group will also be lending its support to further RDD activities in future.
Outline of RDD activities in 2024
In 2024, CMIC will sponsor the following activities to provide knowledge on “rare diseases” for as many CMIC employees, family members, friends, and clients as possible.
- We recruited drawings for the purpose of making rare and intractable diseases known to more people through the network of each employee, and posted the applied pictures on the Japanese CMIC Group website.
- We will hold RDD seminar event for listening to direct voices from rare disease patient for the aim to raise awareness of CMIC employees.
- In order to encourage employee’s donation activities, we set up an intra site dedicated for RDD activities where donations can be deducted directly from their salaries.
- Employees wear a pin RDD badge and have RDD goods in order to make employees themselves aware of those diseases.
Co-hosting of the International Children’s Drawing Contest
CMIC Group and Nakamura Keith Haring Collection co-host the International Children’s Drawing Contest.
This annual contest started in 2009 as the only drawing competition officially recognized by the Keith Haring Foundation. Open to children ages 4 to 17, they have submitted their drawings from schools and painting classes inside and outside Japan, submissions have surpassed 1,000 in recent years. Every year, we invite special guest judges from art and fashion fields. Award winning entries will be exhibited for a week after the award ceremony at the Keith Haring Collection.
Nakamura Keith Haring Collection International Children’s Drawing Contest co-organized by CMIC HOLDINGS Co., Ltd. as part of its social contribution activities, has been designated for “This is MECENAT 2022” by Kigyo Mécénat Kyogikai.
Aims and objectives of co-sponsorship by CMIC Group
Keith Haring is one of the most recognizable and representative of the American art scene in the 1980’s. He was involved in social activities throughout his life such as child welfare education, workshops for children all over the world, and HIV/AIDS prevention awareness activities. Keith Haring also created murals and wall paintings with children in Tama-city, Tokyo in 1987. CMIC Group has inherited the will of Keith Haring who had always wished for children’s future filled with hope, love, and peace. We have supported the Annual Nakamura Keith Haring Collection International Children’s Drawing Contest since 2009. Our objective is to understand different races, religions, cultures, and environments through supporting the contest, provide opportunities for children to freely spread their wings around the global society, and make contributions to the society.
The 16th Annual Nakamura Keith Haring Collection International Children’s Drawing Contest Award Ceremony
Award ceremony was held on November 10, 2024 at the Nakamura Keith Haring Collection located in Kobuchizawa, Hokuto-City, Yamanashi Prefecture.
This year, we have received 1,327 entries from all over the world. 21 winners were chosen as a result of careful review by the judges.
The CMIC Group has embodied its ideals of “bringing about innovation in healthcare fields, so that all may stride forth true to themselves in this one and only life, regardless of age, gender or race” and “whether when the radiant flower of youthful vitality blooms, or as life matures in later age, every desire to live fully in the moment is equally precious” within the CMIC’s CREED.
It is upon the basis of these ideals that we hold up diversity as a management theme of great importance, and lend ourselves to concepts and thinking that enrich by venerating all forms of variety.
Diversity in the CMIC Group is not limited to personnel policies focused on women alone, and by venerating the ways in which our work and thoughts mutually differ, to arrive at yet higher caliber discussion and outcomes, whilst celebrating our variety, it is held up as something that makes us a company able to deliver high performance.
We believe that the employment of diverse personnel, irrespective of race/ gender/ disability, the veneration the contrasts between people to find value, and fair treatment regardless of dissimilarity are indispensable for business growth, and incorporate these beliefs into our advancement of diversity.
Approaches to Medicines for Rare Diseases
In the CMIC Group, we actively carry out our pursuit of medicines for rare diseases, on the basis of our “every desire to live fully in the moment is equally precious” thinking in the CMIC Creed, Our Resolve.
Not only do we lend ourselves to the development of new drugs by various drug manufacturing enterprises aimed at rare illnesses, CMIC also takes an approach whereby we apply for the recognition and sales of new drugs yet unapproved in Japan on our own.
We furthermore make contributions to society through approaches whereby we undertake the acquisition and sales of medicines for rare diseases, from other drug manufacturing enterprises.
Within the CMIC Group Code of Conduct, the CMIC Group recognizes that tackling environmental issues is an essential prerequisite for the continued existence and activities of the corporation, and stipulates that it must take the initiatives in implementing measures aimed at building a decarbonized, recycling-oriented society, addressing environmental risks, and conserving biodiversity.
As of September 2024, the CMIC Group conducts business at 46 locations in Japan (including four plants, seven pharmaceutical development centers) and 15 locations globally (including two plants, one pharmaceutical development center).
In April 2023, CMIC CMO Group, Contract Development and Manufacturing Organization (CDMO) services, entered into a strategic business alliance agreement with Dai Nippon Printing Co., Ltd. In June of the same year, it became an equity-method affiliate from a consolidated subsidiary. Our four plants in Japan have continued to maintain ISO 14001 (the international certification standard for environmental management systems) certification, with each plant working to reduce environmental burdens according to the location and characteristics of the products manufactured. Furthermore, as a mid-term goal for 2030, CMIC CMO Group have set a target of 59% non-fossil power consumption rate for each plant in Japan. In 2024, CMIC CMO Group introduced a solar power generation system at the Toyama Plant, and are also working to improve the resource recycling rate and reduce water consumption.
CMIC CMO Group also established an Environment, Health and Safety (EHS) Promotion Committee to continuously review, educate, and improve management systems at its four plants in Japan for the purposes of environmental conservation and employee health and safety promotion.
Furthermore, all of our pharmaceutical development centers that conduct non-clinical business are also giving consideration to the environment by taking measures to deal with toxic substances and waste. We are also working to calculate and reduce CO2 emissions and industrial waste emissions not only at our plants but across the CMIC Group.
LNG satellite facility and small boiler facility
Carp swimming in the final drainage pond
Solar panels at Toyama Plant
ISO 14001-certified Business Sites
| Company name | Business Site | Certifying Body | Certification Number |
| CMIC CMO Co., Ltd. | Shizuoka Plant* | KHK-ISO Center | 01ER・157 |
| Toyama Plant | JSA-SOL | JSAE056 | |
| Ashikaga Plant | KHK-ISO Center | 01ER・140 | |
| Nishine Plant | KHK-ISO Center | 20ER・1103 |
* Shizuoka Plant scope of registration: Includes CMIC Bio Co., Ltd.
CO2 emissions
| 2022 | 2023 | 2024 | |
| SCOPE1（thousand tons CO2） | 14 | 1 | 1 |
| SCOPE2（thousand tons CO2） | 29 | 7 | 7 |
| Total Scope 1, Scope 2 (thousand tons CO2) | 44 | 8 | 8 |
Scope:
The fiscal years ending September 2022 and September 2023 : Consolidated group companies in Japan
Since CMIC CMO Group became an equity-method affiliate in the fiscal year ended September 30, 2023, it has been excluded from the calculation of emissions starting from the beginning of that fiscal year.
The fiscal year ending September 2024 : In addition to the consolidated group companies in Japan, CMIC, INC. in the U.S. is calculated.
